| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $0 | — | -100.0% |
| R&D Expense | $46.4M | — | +25.8% |
| SG&A Expense | $12.9M | — | +21.1% |
| Operating Income | -$59.3M | — | -32.9% |
| Net Income | -$53.8M | — | -29.3% |
| EPS (Basic) | -$0.48 | — | +7.7% |
| EPS (Diluted) | -$0.48 | — | +7.7% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $582.7M | -10.8% | +126.2% |
| Current Assets | $594.3M | -10.1% | +83.9% |
| Total Assets | $619.8M | -9.3% | +80.9% |
| Current Liabilities | $27.4M | -39.1% | -11.0% |
| Total Liabilities | $31.1M | -36.3% | -12.5% |
| Stockholders' Equity | $588.7M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$58.6M | — | -10.5% |
| Capital Expenditures | $3.0M | — | -18.1% |
| Investing Cash Flow | -$12.0M | — | -336.1% |
| Financing Cash Flow | -$135K | — | -100.1% |
| Free Cash Flow | -$61.6M | — | -8.7% |
| +91.7% |